Abstract 350P
Background
Currently, various chemotherapy regimens have been reported for the efficacy of unresectable squamous cell carcinoma (cSCC). However, there is no clear consensus. Here, we report the treatment results of unresectable cSCC in which concurrent chemoradiotherapy (CCRT) combining low-dose cisplatin and 5-fluorouracil (low-dose FP therapy) was performed in our department.
Methods
A two-year retrospective study was conducted for 23 patients who had been received CCRT with low-dose FP therapy for unresectable cSCC. The patient age ranged from 44 to 79 years (mean age, 71 years), and gender was 17 men and 6 women. The primary lesions of unresectable cSCC were present in 7 cases in the head and neck, in 1 case in the upper limbs, in 5 cases in the lower limbs, and in 10 cases in the perineal region. Radiotherapy (RT) of CCRT had irradiated the primary lesion and regional lymph nodes. And for chemotherapy of CCRT, low-dose FP therapy was used.
Results
When 23 patients were classified by TNM staging (UICC 8th), stage 3 of unresectable cSCC was 5 patients (21.7%) and stage 4 was 18 patients (78.3%). 6 cases who those with stage 4 were dead (26.1%), while there were no dead cases who those with stage 3. Overall response rate (ORR) was 81 %, and median progression-free survival (PFS) was 392 days. For stage 4 of unresectable cSCC, one-year overall survival (OS) was 78 %, two-year OS was 56.7%, median survival time (MST) was 560 days.
Conclusions
CCRT with low-dose FP therapy is an effective treatment for unresectable cSCC. However, tumors of the primary lesion and / or regional lymph nodes may remain after CCRT. In such cases, chemotherapy (i.e., maintenance therapy [MT]) should be continued after CCRT. In our department, most cases of unresectable cSCC receive MT after CCRT. Therefore, in the first treatment of unresectable cSCC, it is important how to make the tumor smaller. In this study, our cases had optimal results of ORR, median PFS, OS, and MST. According to these facts and results, we considered CCRT with low-dose FP therapy suppressed cSCC and is an effective treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
9P - XRCC1 Arg194Trp, Palb2 T1100T (3300T>G), HMMR V353A, TNF aG308A polymorphisms as diagnostic and prognostic markers of breast cancer in the Kyrgyz ethnic group
Presenter: Aigul Semetei kyzy
Session: Poster display session
Resources:
Abstract
232P - Early Results from the Phase I Study of SY-1365, a Potent and Selective CDK7 inhibitor, in Patients with Ovarian Cancer and Advanced Solid Tumors
Presenter: Debra Richardson
Session: Poster display session
Resources:
Abstract
382P - Drug metabolizing enzymes pharmacogenomic: Biomarkers for improved chemotherapy in head and neck cancer squamous cell carcinoma
Presenter: Sunishtha Bhatia
Session: Poster display session
Resources:
Abstract
401P - Women in oncology: Alarming figures from India
Presenter: Sharada Mailankody
Session: Poster display session
Resources:
Abstract
416P - Multidisciplinary management of sarcomas of the head and neck: An institutional experience
Presenter: Kavitha Jain
Session: Poster display session
Resources:
Abstract
523P - Co-morbilities and survival of patients initially diagnosed with extensive-stage small cell lung cancer: Impact of hypertension, diabetes and chronic hepatitis B viral infection
Presenter: Weigang Xiu
Session: Poster display session
Resources:
Abstract
529P - Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study
Presenter: Roni Gillis
Session: Poster display session
Resources:
Abstract